Michael Cunyuan Chen
Co-Founder & Chief Scientific OfficerDr. Michael Cunyuan Chen, PH.D., is Co-Founder of Seaport Therapeutics, Inc. and serves as its Chief Scientific Officer since May 2024. He is Chief Scientific Officer of Seaport of PureTech Health plc from May 2024. In his most recent role, Dr. Chen was the Head of Innovation at PureTech Health, where he oversaw the rapid advancement of the neuropsychiatric medicines that led to the launch of Seaport. These novel medicines are being advanced within Seaport’s clinical-stage pipeline powered by the Glyph platform, which leverages the lymphatic system to create new medicines based on clinically validated mechanisms. Dr. Chen was previously Co-founder and Head of Research and Strategy at Sonde Health, a company developing vocal biomarkers for depression and other neuropsychiatric disorders. He was a postdoctoral fellow at Beth Israel Deaconess Medical Center and Harvard Medical School, Department of Neurology. Dr. Chen completed his Ph.D. at Stanford University, focusing on the neurobiological mechanisms of risk for depression and sleep disorders. He received a B.A. from Yale University.
Positions
- Company NameSeaport Therapeutics, Inc.Stock CodeSPTXPositionCo-Founder & Chief Scientific OfficerColleagues
- SMSteven M. PaulFounder & Non-Employee Chair of the Board
- DZDaphne ZoharFounder, CEO, President & Director
- ALAntony LoebelChief Medical Officer & President of Clinical Development
- LALauren A. WhiteChief Financial Officer
- DMDenice M. TorresLead Independent Non-Employee Director
- SESandra E. PetersonIndependent Non-Employee Director
- RJRobert J. HombachIndependent Non-Employee Director
